The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present disclosure relates to new spiro[2.5]octane compounds of formula I and pharmaceutically acceptable salts thereof; to their use in medicine; to pharmaceutical compositions containing them; to processes for their preparation; and to intermediates used in such processes. The spiro[2.5]octane compounds may be useful in the treatment and amelioration of obesity. Formula (I).
A61P 25/00 - Drugs for disorders of the nervous system
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
3.
MEDIA AND FERMENTATION METHODS FOR PRODUCING POLYSACCHARIDES IN BACTERIAL CELL CULTURE
The present invention relates to media and fermentation methods for producing polysaccharides in bacterial cell culture. In one aspect, the invention relates to a complex culture medium comprising a vegetable hydrolysate, a yeast extract, and a carbon source. In another aspect, the invention relates to a defined media having a total amino acid concentration greater than about 50 mM. A further aspect of the invention relates to the use of fed batch and perfusion fermentation methods for cultivating polysaccharide-producing bacteria.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Medical information services, namely providing medical information in the field of pharmaceutical preparations for the treatment of autoimmune and inflammatory diseases and disorders; information, advisory and consultancy services in the field of medical care and medical treatment services, namely providing a patient support program with live support for pharmaceutical treatments as well as drug reimbursement and access assistance
5.
USE OF A SPRAY FREEZE-DRYING PROCESS FOR THE LYOPHILIZATION OF A mRNA-ENCAPSULATING LIPID NANOPARTICLES FORMULATION
The invention relates to the lyophilization of a liquid pharmaceutical formulation including lipid nanoparticles encapsulating mRNA.
The invention relates to the lyophilization of a liquid pharmaceutical formulation including lipid nanoparticles encapsulating mRNA.
According to the invention, a spray freeze-drying process is used to achieve the lyophilization.
The invention relates to the lyophilization of a liquid pharmaceutical formulation including lipid nanoparticles encapsulating mRNA.
According to the invention, a spray freeze-drying process is used to achieve the lyophilization.
The invention is of particular interest for the lyophilization of mRNA vaccine formulations.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
6.
PROCESS FOR PREPARING N-(6-((1H-PYRAZOL-1-YL)METHYL)-4-METHOXYBENZO[D]ISOXAZOL- 3-YL)-2-METHOXYBENZENESULFONAMIDE
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The invention provides method of using antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The method of using the antibodies include method of treating disease. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
The present disclosure relates to processes and intermediates that are useful for preparing Compound 1 having the formula Compound 1: or a salt thereof.
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
9.
COAXIAL FLOW DEVICE FOR NANOPARTICLE PREPARATION AND MANUFACTURING EQUIPMENT INCLUDING SUCH DEVICE
The invention relates to a coaxial flow device 1 capable of creating comparable microenvironments at various operation scales through the continuous introduction and mixing of nanoparticle precursor solutions for the manufacturing of a dispersion comprising nanoparticles. According to the invention, the device includes first and second coaxial tubes 3, 5 for controlled flows of nanoparticle precursor solutions and a mixing portion 7, wherein a disrupting physical element 21 is arranged to cause formation of the microenvironments. Application to the production of mRNA vaccines.
B01F 25/313 - Injector mixers in conduits or tubes through which the main component flows wherein additional components are introduced in the centre of the conduit
B01F 25/4314 - Straight mixing tubes with baffles or obstructions that do not cause substantial pressure dropBaffles therefor with helical baffles
B01F 25/441 - Mixers in which the components are pressed through slits characterised by the configuration of the surfaces forming the slits
B01F 25/442 - Mixers in which the components are pressed through slits characterised by the relative position of the surfaces during operation
B01F 25/452 - Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces
B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions
The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Clostridioides difficileC. difficileC. difficileC. difficileC. difficile toxoid and an adjuvant, wherein the composition is administered two or three times.
The present disclosure provides methods and compositions for treating inflammatory bowel disease (IBD), e.g., ulcerative colitis (UC) or Crohn's disease (CD), with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
14.
Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents
Various forms of cancer and other diseases are treated using a medicinal combination of a SIRPαFc to block binding with CD47, and an anti-VEGF agent such as humanized antibody bevacizumab to control vascularization.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided herein are systems and methods for performing biological assays using a thermally sealed valve and/or incubation chamber. The systems and methods determine one or more characteristics of a nucleic acid amplification sample based on a modified optical property of the sample.
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, W and m, n, o and p are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, W and m, n, o and p are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of vaso-occlusive crisis;; Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations for the treatment of sickle cell disease.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders;; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes;; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Smoking cessation preparations; Antifungal preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use; Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, and viral diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations for the treatment of of vaso-occlusive crisis; Pharmaceutical preparations for the treatment of sickle cell disease
This disclosure pertains to the preparation of bifunctional compounds (e.g., Compound 1), intermediates in the preparation of such compounds, and preparation of such intermediates.
C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
22.
PONSEGROMAB FOR USE IN TREATING CACHEXIA IN CANCER PATIENTS
The invention is directed to methods of treating cancer cachexia or cancer by administering to the patient a GDF15 antibody ponsegromab, and especially while the patient is receiving a systemic chemotherapy.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
23.
COAXIAL MIXING DEVICE FOR NANOPARTICLE PREPARATION AND MANUFACTURING EQUIPMENT INCLUDING SUCH MIXING DEVICE
The invention relates to a coaxial flow device (1) capable of creating comparable microenvironments at various operation scales through the continuous introduction and mixing of nanoparticle precursor solutions for the manufacturing of a dispersion comprising nanoparticles, the device including, coaxially arranged, a first tube (3), an annular second tube (5), a central third tube (7) and a tubular mixing portion (9) arranged downstream of said tubes. According to the invention, the outlet (15) of the annular second tube (5) is formed by a plurality of discrete openings (21) designed to cause formation of the microenvironments. Application to the production of RNA, in particular mRNA, or DNA vaccines.
B01F 25/313 - Injector mixers in conduits or tubes through which the main component flows wherein additional components are introduced in the centre of the conduit
B01F 25/00 - Flow mixersMixers for falling materials, e.g. solid particles
24.
METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH AN ANTI-TL1A ANTIBODY
The present disclosure provides methods and compositions for treating inflammatory bowel disease (IBD), e.g., ulcerative colitis (UC) or Crohn's disease (CD), with a therapeutic dose of an anti-TNF-like ligand 1A (TL1 A) antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
25.
ALUMINUM ADJUVANT NANOPARTICLES, METHODS OF MANUFACTURE, AND USES THEREOF
In one aspect, the present disclosure relates to adjuvant nanoparticles comprising aluminum and/or CpG oligodeoxynucleotides. In particular embodiments, the nanoparticles have an average size of less than about 100 nm. Also provided herein are methods of making the nanoparticles using a microfluidic device.
The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and/or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and/or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C07D 213/64 - One oxygen atom attached in position 2 or 6
C07D 213/68 - One oxygen atom attached in position 4
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and/or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and/or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
28.
METHOD FOR STERILIZING AND FILLING CONTAINERS FOR PHARMACEUTICAL PRODUCT AND RELATED FILLING SYSTEM
The invention relates to a method for sterilizing containers and filling said containers in sterile conditions with a pharmaceutical product, comprising the steps of: - providing a plurality of internally sterile empty containers (1); - performing a filling cycle, comprising the sequential steps of o introducing a group of empty container(s) (1) into a filling enclosure (55); o sterilizing an external surface of the empty container(s) (1) by application of electron beam radiation emitted by an electron beam emitter (73); o introducing a filling needle (75) into each container body (3) and dispensing pharmaceutical product through the filling needle (75); o extracting the group of filled container(s) (1); - repeating a filling cycle with a subsequent group of empty container(s), The power of the electron beam radiation is modulated during the filling cycle between a maximum value and a minimum value, different from the maximum value and different from zero, whereby a plurality of filling cycles are carried out without switching off the electron beam emitter (73). The invention is also directed to a related filling system.
B65B 55/08 - Sterilising wrappers or receptacles prior to, or during, packaging by irradiation
B65B 55/10 - Sterilising wrappers or receptacles prior to, or during, packaging by liquids or gases
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
The invention relates to a syringe comprising an elongated main body having a nozzle formed at a distal end thereof and a threaded connection part at least partially surrounding the nozzle. The main body is made by co-injection molding from at least two different materials and the threaded connection part is made of a plastic material by injection molding, with the main body and the threaded connection part being overmolded one to the other. The invention also relates to a method of manufacturing such a syringe.
Dosing regimens and methods for administering SIRPaFc fusion proteins are provided. The dosing regimens and methods include both SIRPaFc monotherapies and combination therapies.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use; Pharmaceutical preparations for use as muscle relaxants during surgery or mechanical ventilation; Pharmaceutical preparations for rapidly reversing the effects of certain muscle relaxants given during surgery; Pharmaceutical preparations for preventing or treating low blood pressure during surgery; Syringes sold filled with pharmaceuticals for use in medical operating rooms
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use; Pharmaceutical preparations for use as muscle relaxants during surgery or mechanical ventilation; Pharmaceutical preparations for rapidly reversing the effects of certain muscle relaxants given during surgery; Pharmaceutical preparations for preventing or treating low blood pressure during surgery; Syringes sold filled with pharmaceuticals for use in medical operating rooms
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use; Pharmaceutical preparations for use as muscle relaxants during surgery or mechanical ventilation; Pharmaceutical preparations for rapidly reversing the effects of certain muscle relaxants given during surgery; Pharmaceutical preparations for preventing or treating low blood pressure during surgery; Syringes sold filled with pharmaceuticals for use in medical operating rooms
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07C 215/40 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
40.
METHOD AND APPARATUS FOR IMPROVED MAN-MACHINE INTERACTIONS
An automated smart voice-interactive platform allows users to securely register with a provider and have physical conditions monitored, in place of interacting with a variety of human workers, in a fault tolerant and adaptive manner such that interactions improve with each additional user interaction.
G10L 15/183 - Speech classification or search using natural language modelling using context dependencies, e.g. language models
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G10L 15/22 - Procedures used during a speech recognition process, e.g. man-machine dialog
G10L 15/30 - Distributed recognition, e.g. in client-server systems, for mobile phones or network applications
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
41.
METHOD AND SYSTEM OF SIMULATING OPERATIONAL INTEGRITY OF A PRE-FILLED VIAL
Method and system of digitally simulating operational integrity of a pre-filled vial. The method includes simulating, in a processor of a computing system, a frictional disengaging of a stopper from the pre-filled vial responsive to a progressively decreasing ambient pressure, the pre-filled vial containing a gaseous portion that is separated from ambient air by the stopper, and generating, by the processor in accordance with the progressively decreasing ambient pressure, a measure corresponding to an aircraft altitude at which the frictional disengaging is initiated.
G06F 30/28 - Design optimisation, verification or simulation using fluid dynamics, e.g. using Navier-Stokes equations or computational fluid dynamics [CFD]
42.
METHOD AND APPARATUS FOR IMPROVED HUMAN-MACHINE INTERACTIONS
An automated smart voice-interactive platform allows users to securely register with a provider and have physical conditions monitored, in place of interacting with a variety of human workers, in a fault tolerant and adaptive manner such that interactions improve with each additional user interaction.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G06T 13/40 - 3D [Three Dimensional] animation of characters, e.g. humans, animals or virtual beings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Smoking cessation preparations; Vaccines for human use
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Described herein are compounds of Formula (I): I and their pharmaceutically acceptable salts, wherein R1, R2, R3, Rp, A1, L1, L2, T1, T2, T3, T4, n1, t1, t2, and t3 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
48.
ORAL COMPOSITIONS/FORMULATIONS OF 2-({4-[(2S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYL-1,3-BENZODIOXOL-4-YL]PIPERIDIN-1-YL}METHYL)-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID OR A PHARMACEUTICALLY SALT THEREOF
The invention relates to immediate-release oral pharmaceutical compositions and oral controlled release swellable core technology (SCT) tablets of 2-({4-[(2S)-2-(4-chloro-2- fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid (Compound 1) or a pharmaceutically acceptable salt thereof (e.g. tris salt of Compound 1) and process of making such compositions and tablets. The present invention further relates to methods of using these compositions and tablets once daily for weight management control or for treating, e.g., T2DM, obesity, or overweight.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
56.
GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF
Described herein are compounds of Formula I:
Described herein are compounds of Formula I:
Described herein are compounds of Formula I:
and their pharmaceutically acceptable salts, wherein R1, R2, R3, Rp, A1, L1, L2, T1, T2, T3, T4, n1, t1, t2, and t3 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
57.
IMPROVED METHODS FOR PRODUCING GLYCOCONJUGATES BY REDUCTIVE AMINATION IN APROTIC SOLVENT
The present disclosure relates to media and fermentation methods for polysaccharide production in bacterial cell culture. In one aspect, the disclosure relates to cell culture media comprising potassium phosphate and calcium chloride. In another aspect, the disclosure relates to a method of fermenting bacterial cell culture under pressurized conditions. The media and methods disclosed herein are useful for increasing the polysaccharide production and reducing the lag phase of a bacterial cell culture, i.e., Streptococcus pneumoniae.
The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
72.
Process for Producing of Vaccine Formulations With Preservatives
The present invention relates to a process for the production of a conjugate vaccine comprising a preservative. The invention relates in particular to a process for the production of a conjugate vaccine where the preservative is hydrophobic and viscous (such as 2-phenoxyethanol (2-PE)).
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
73.
TMPRSS2-ERG AND RB1 AS PREDICTIVE BIOMARKERS FOR TREATMENT WITH A PARP INHIBITOR
This invention relates to methods for selecting patients having prostate cancer for treatment with a PARP inhibitor, such as talazoparib, or a pharmaceutically acceptable salt thereof, and an androgen receptor inhibitor, such as enzalutamide, or a pharmaceutically acceptable salt thereof, comprising: i) determining an ERG gene alteration status, wherein the ERG gene alteration is a TMPRSS2-ERG gene fusion/rearrangement, and/or determining an RB1 gene alteration status, from a biological sample of the prostate cancer from the subject; and ii) selecting patients with the TMPRSS2-ERG gene fusion/rearrangement and/or the RB1 gene alteration for treatment.
The invention relates to an injection device comprising a housing, a needle connection (55) for attaching a needle (61) to a cartridge (7) received in the housing (2), an injection drive mechanism (9), an electronic control system for controlling the injection drive mechanism (9) and a needle sensing feature for detecting the attachment of a needle (61) to the cartridge (7). The needle sensing feature includes a slider (13) comprising a magnetic part and an electromagnetic sensor (203) arranged within the housing (2), such that the magnetic part can move between positions remote from the electromagnetic sensor (203) and a position in the vicinity of the electromagnetic sensor (203), when the slider (13) is in its retracted position, wherein the electromagnetic sensor (203) is caused to generate a signal indicative of a needle (61) being attached to the cartridge (7).
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/34 - Constructions for connecting the needle
The invention relates to polypeptides and RNA molecules encoding an E. coli fimbrial antigen PapG mutant. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the polypeptides, RNA molecules, RNA-LNPs and compositions thereof for the prevention of E.coli infection, including urinary tract infection.
Methods for identifying a subject eligible to receiving a therapeutic amount of a CDK4 inhibitor, predicting whether a subject is sensitive to treatment with a CDK4 inhibitor and methods of treating cancer are disclosed. The methods are based on measurement of mRNA expression, protein expression, and/or activity of cyclin-dependent kinase 6 (CDK6), cyclin E1 (CCNE1), cyclin D1 (CCND1), and/or Androgen Receptor (AR).
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The invention relates to compounds of Formula I
The invention relates to compounds of Formula I
The invention relates to compounds of Formula I
and pharmaceutically acceptable salts thereof wherein R1, R2, R3, p, q, q′ and Ring A are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Provided herein are cells, compositions, and related methods for improved cell growth. The expression of one or more of CBS, CTH, and GNMT genes is increased. In some embodiments, nucleic acid constructs, vectors, host cells and related compositions and methods for generating and selecting cysteine prototroph cells are provided.
This invention relates to therapies for treating cancers in a subject comprising a cyclin dependent kinase 4 (CDK4) inhibitor, and optionally in combination with a CDK2 or an additional anti-tumor agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
This invention relates to therapies for treating mantle cell lymphoma comprising a cyclin dependent kinase 4 (CDK4) inhibitor or a pharmaceutically acceptable salt thereof, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
86.
FORMULATIONS COMPRISING N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDE COMPOUNDS AND USES THEREOF
The present disclosure relates to compositions comprising N-substituted-dioxocyclobutenylamino-3-hydroxy-picoliamide compounds or a pharmaceutically acceptable salt or hydrate thereof, methods of preparing said compositions, and uses thereof. The compositions may be useful in the treatment of conditions ameliorated by inhibition of CC chemokine receptor 6.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and/or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and/or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
E. coliE. coli lipopolysaccharides. In one embodiment, the O-polysaccharide molecules are conjugated to streptococcal C5a peptidase (SCP). In some embodiments, the O-polysaccharide molecules are conjugated to SCR using click chemistry.
This disclosure relates to the novel processes for the synthesis of (1H-pyrazol-5-yl)cyclopentyl carbamate compounds, to novel intermediates useful for the synthesis of (1H-pyrazol-5-yl)cyclopentyl carbamate compounds, and to the synthesis of said intermediates.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
The invention relates to vaccination of human subjects, in particular elderly, against bacterial infections, wherein the bacterial infection is not pneumococcal, and COVID-19 infections.
